首页|阿加曲班联合阿司匹林对急性脑梗死患者血清炎性因子及神经损伤的影响

阿加曲班联合阿司匹林对急性脑梗死患者血清炎性因子及神经损伤的影响

扫码查看
目的 探讨阿加曲班联合阿司匹林对急性脑梗死患者血清炎性因子及神经损伤的影响.方法 选择急性脑梗死患者 68 例,按随机数字表法分为对照组(34 例)及观察组(34 例).对照组采用阿司匹林治疗,观察组在对照组基础上采用阿加曲班治疗.对比两组血清炎性因子[基质金属蛋白酶-9(MMP-9)、肿瘤坏死因子-α(TNF-α)、脂蛋白相关磷脂酶A2(Lp-PLA2)]水平、血管内皮功能[一氧化氮(NO)、内皮素-1(ET-1)、肱动脉血流介导的舒张功能(FMD)]水平、神经功能损伤程度[美国国立卫生研究院卒中量表(NIHSS)评分]及不良反应发生情况.结果 治疗后,两组MMP-9、TNF-α、Lp-PLA2 水平较本组治疗前低,且观察组MMP-9(137.52±3.67)μg/L、TNF-α(7.59±0.52)μg/L、Lp-PLA2(12.83±1.54)pg/ml较对照组的(165.72±4.83)μg/L、(11.28±0.93)μg/L、(17.64±1.93)pg/ml低,差异有统计学意义(P<0.05).治疗后,两组NO、FMD较本组治疗前高,ET-1 较本组治疗前低;且观察组NO(65.73±8.56)μmol/L、FMD(13.46±2.35)%较对照组的(53.62±7.42)μmol/L、(10.84±1.72)%高,ET-1(52.71±4.32)ng/L较对照组的(68.92±5.67)ng/L低,差异有统计学意义(P<0.05).治疗后,两组NIHSS评分较本组治疗前低,且观察组NIHSS评分(16.53±2.14)分较对照组的(22.61±2.87)分低,差异有统计学意义(P<0.05).两组不良反应发生率比较,差异无统计学意义(P>0.05).结论 对急性脑梗死患者采取阿加曲班与阿司匹林联合用药方案,可有效改善机体内炎性因子水平、血管内皮功能,并降低患者神经功能损伤程度,具有良好的安全性.
The effect of argatroban combined with aspirin on serum inflammatory factors and nerve damage in patients with acute cerebral infarction
Objective To explore the effect of argatroban combined with aspirin on serum inflammatory factors and nerve damage in patients with acute cerebral infarction.Methods 68 patients with acute cerebral infarction were selected and divided into a control group(34 cases)and an observation group(34 cases)using a random number table method.The control group was treated with aspirin,while the observation group was treated with argatroban on the basis of the control group.Comparison was made on the levels of serum inflammatory factors[matrix metalloproteinase-9(MMP-9),tumor necrosis factor-α(TNF-α),lipoprotein-associated phospholipase A2(Lp-PLA2)],vascular endothelial function[nitric oxide(NO),endothelin-1(ET-1),and flow-mediated dilation(FMD)]level,degree of neurological damage[National Institutes of Health Stroke Scale(NIHSS)score],and occurrence of adverse reactions between the two groups.Results After treatment,the levels of MMP-9,TNF-α and Lp-PLA2 in both groups were lower than those before treatment;the observation group had MMP-9 of(137.52±3.67)μg/L,TNF-α of(7.59±0.52)μg/L,and Lp-PLA2 of(12.83±1.54)pg/ml,which were lower than(165.72±4.83)μg/L,(11.28±0.93)μg/L,and(17.64±1.93)pg/ml in the control group;the difference was statistically significant(P<0.05).After treatment,NO and FMD in both groups were higher than those before treatment,and ET-1 was lower than that before treatment;the observation group had NO of(65.73±8.56)μmol/L and FMD of(13.46±2.35)%,which were higher than(53.62±7.42)μmol/L and(10.84±1.72)%in the control group;ET-1 of(52.71±4.32)ng/L in the observation group was lower than(68.92±5.67)ng/L in the control group;the difference was statistically significant(P<0.05).After treatment,the NIHSS score in both groups was lower than that before treatment;the NIHSS score of(16.53±2.14)points in the observation group was lower than(22.61±2.87)points in the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The combined use of argatroban and aspirin in patients with acute cerebral infarction can effectively improve the levels of inflammatory factors and vascular endothelial function,and reduce the degree of nerve damage in patients,with good safety.

Acute cerebral infarctionArgatrobanAspirinSerum inflammatory factorsVascular endothelial functionNerve damageAdverse reactions

刘勇、李伟

展开 >

277400 枣庄市台儿庄区人民医院神经内科

277400 枣庄市台儿庄区人民医院心电图室

急性脑梗死 阿加曲班 阿司匹林 血清炎性因子 血管内皮功能 神经功能损伤 不良反应

2024

中国实用医药
中国康复医学会

中国实用医药

影响因子:0.797
ISSN:1673-7555
年,卷(期):2024.19(19)